"Neuroplasticity" Claims: What Has and Has Not Been Shown

What the claim says

"Psychedelics rewire the brain" or "open a window of neuroplasticity" are common statements. Neuroplasticity means the brain's ability to change its connections. The research behind these statements is real, but most of it is in cells and animals. This page separates what has been shown in each setting. Evidence labels: preclinical (cells/animals only), mixed, insufficient evidence and Proper evidence not found.

In cells and animals

• Researchers reported that serotonergic psychedelics robustly increase growth of new neuron branches and connection points (neuritogenesis and spinogenesis) in vitro (in cell cultures) and in vivo (in living animals). [1]
• A 2023 study reported that LSD and psilocin bind directly to TrkB, the receptor for the growth protein BDNF, and that effects on plasticity and antidepressant-like behavior in mice depend on that binding. [2]

Label: preclinical (cells/animals only). These findings generate hypotheses. They are not proof that the same changes occur, or matter, in people. Animal and cell results should not be carried over to people. See Reading Early-Stage Research.

In people: a blood marker

BDNF is a growth protein. Some studies have used its level in blood as a stand-in for plasticity. A 2025 meta-analysis of 29 human studies of ketamine, esketamine, LSD, psilocybin, ayahuasca, DMT, MDMA and other plasticity-promoting drugs found no evidence that they elevate peripheral BDNF levels in humans. [3] Studies with better-controlled designs reported smaller effects, and the authors raised the possibility that the preclinical findings may not translate to human subjects, or that blood BDNF is simply not an informative marker. [3]

Label: mixed to insufficient evidence for blood BDNF as evidence of plasticity. A blood marker is also a biomarker, and a biomarker change is not the same as a clinical benefit.

In people: brain imaging

A 2022 study in depression used brain imaging in two trials. After psilocybin therapy, 5-HT2A receptor-rich networks became more interconnected, and the authors proposed that antidepressant action may depend on a global increase in brain network integration. [4] That is a pattern linked with symptom improvement, not a direct measurement of new connections between neurons. It was observed in patients receiving psilocybin therapy, not in microdosers.

Label: promising but limited, as an association in small groups of patients.

In people: clinical outcomes

Some psilocybin trials show improvement in depression scores. For example, a randomized trial in major depression (104 people) compared psilocybin with a niacin placebo and found significantly lower depression scores with psilocybin by day 43. [5] Improvement in symptoms does not demonstrate plasticity as the cause. See One Session Cures Everything Claims and Proposed Mechanisms vs Proven Clinical Outcomes.

What about microdosing?

Proper evidence not found for human evidence that microdosing produces lasting structural plasticity. We searched PubMed on October 22, 2026 for human studies on psychedelics and neuroplasticity and found animal and cell research, blood marker analyses and imaging in patients receiving full sessions, but no controlled microdosing study showing structural change. One microdosing meta-analysis noted that psilocybin altered brain electrical activity (EEG) and speech with little behavioral change. [6] A change in a measurement is not a benefit.

Summary table

Practical takeaway

Treat "neuroplasticity" as an interesting hypothesis, not a promise. It is a poor basis for deciding to use any substance. Safety information is in Psychedelic Adverse Effects and Contraindications.